Genesis Private Equity Fund III (GPEF III ) of the Genesis Capital group sold its 85.9% interest in QUINTA-ANALYTICA, a major Czech provider of research and regulatory services to the pharmaceutical and biotechnology industries and producers of generic pharmaceuticals. The HAVEL & PARTNERS’ team provided Genesis Capital with comprehensive legal services related to the sale of the stake, which was acquired by LVA Holding from the portfolio of BBA Capital Partners.
Legal advice in this significant transaction in the pharmaceutical industry was provided to the seller by Václav Audes (Partner), Veronika Filipová (Senior Associate), and Filip Pavlík (Legal Assistant).
Genesis Capital offers small and medium-sized enterprises in Central Europe assistance in financing their growth and development. The group has been cooperating with HAVEL & PARTNERS on a long-term basis; in 2016 the firm’s legal team also provided comprehensive legal services during the company’s entry into QUINTA-ANALYTICA. The share purchase at that time was a prime example of how succession issues are to be handled. GPEF III became the majority owner of QUINTA and kick-started its growth strategy.
QUINTA-ANALYTICA, headquartered in Prague, is one of the largest independent companies in Central and Eastern Europe in the field of services for the pharmaceutical industry and the production of generic pharmaceuticals. It specialises in pharmacokinetics and BA/BE clinical trials, bioanalytics, analyses of medicinal products, quality control, stability studies, and other specific services.
During its six-year partnership with Genesis Capital, the company has expanded its portfolio of services, diversified its customer portfolio, and continued to grow not only in Europe but also in North America. Jan Tauber, chairman of Genesis Capital Equity, says: “Over the six years of the partnership, the management has safely guided the company through difficult periods, most notably the period of negative impacts of the COVID-19 pandemic. The company is currently in good shape, ready for further growth and development with a new owner.”
QUINTA-ANALYTICA employs over 200 experienced professionals who provide a broad portfolio of services to the largest global companies in the pharmaceutical industry. In 2020, it opened a modern and innovative laboratory in Brno. In 2021, the company aims to generate revenues of €16 million.
